01—Abstract
Summary
Summary of the 10-Q filed April 30, 2025. Cited figures are marked; the original filing is the authoritative source.
Guardant Health, Inc. reported a notable increase in revenue for the first quarter of 2025, up 21% year-over-year to $203.5 milliona.
This growth was primarily driven by strong performance in its Oncology and Biopharma and data segments, reflecting increased test volumes and improved reimbursement for key tests like Guardant360 CDx and Guardant Reveal. The company also saw the initial revenue contribution from its Shield screening test, a positive development for its early cancer detection strategy. Despite the revenue growth, the company continued to incur significant operating losses, with a net loss of $95.2 millionb for the quarter.
This was partly due to increased investments in research and development and a substantial rise in sales and marketing expenses, particularly related to expanding its commercial team and supporting new product launches like Shield. The company's cash position remains strong at over $800 millionc, providing runway for continued investment. Investors will be closely watching the company's progress in commercializing its screening tests and managing its expenses to achieve profitability.
02—Key points
Key Highlights
- Revenue increased by 21% to $203.5 million in Q1 2025, driven by growth in Oncology and Biopharma segments.
- Significant increase in sales and marketing expenses (up 30%) to support commercial team expansion and product launches.
- Net loss for the quarter was $95.2 million, a slight improvement from $115.0 million in the prior year period.
- Screening revenue, primarily from the Shield test, generated $5.7 million in the quarter.
- Cash, cash equivalents, and restricted cash stood at $803.9 million as of March 31, 2025.
- The company completed a note exchange, retiring $659.3 million of 2027 Notes for $600.0 million of new 2031 Notes, resulting in a $13.7 million gain on extinguishment.
- An impairment of $5.0 million was recorded for one non-marketable equity security investment.
03—One dollar
Follow one dollar
For each $1.00 of revenue in Q1 FY2025, Guardant Health, Inc. lost $0.47.
- Revenue$203.5M100.0%
- Cost of revenue−$74.7M36.7%
- Gross profit$128.7M63.3%
- Operating costs−$239.8M117.8%
- Operating income−$111.0M54.6%
- Interest, other & tax$15.9M7.8%
- Net income−$95.2M46.8%
04—Financials
Financial Highlights
Figures from 10-QQ1 FY2025filed April 30, 2025Financial Statements
Q1 FY2025 against Q1 FY2024
| Line item | Q1 FY2025Q1 FY2024 | Change |
|---|---|---|
| Revenue | $203.47M$168.49M | +20.8% |
| Cost of Revenue | $74.72M$65.30M | +14.4% |
| Gross Profit | $128.75M$103.19M | +24.8% |
| R&D Expenses | $88.52M$83.80M | +5.6% |
| Operating Expenses | $314.51M$268.17M | +17.3% |
| Operating Income | -$111.04M-$99.68M | −11.4% |
| Interest Expense | $791K$645K | +22.6% |
| Net Income | -$95.16M-$114.98M | +17.2% |
| EPS (Basic) | $-0.77$-0.94 | +18.1% |
| EPS (Diluted) | $-0.77$-0.94 | +18.1% |
| Shares Outstanding (Basic) | 123.87M121.71M | +1.8% |
| Shares Outstanding (Diluted) | 123.87M121.71M | +1.8% |
05—Questions
Frequently Asked Questions
What is Guardant Health's revenue performance for the first quarter of 2025?
Guardant Health reported a 21% increase in total revenue, reaching $203.5 million for the three months ended March 31, 2025, compared to $168.5 million in the same period of 2024. This growth was mainly attributed to higher test volumes in the Oncology and Biopharma and data segments, along with improved reimbursement rates for key tests.
How did the company manage its expenses in the quarter, and what was the impact on profitability?
While revenue grew, operating expenses also increased. Cost of revenue rose 14% to $74.7 million, research and development expenses increased 6% to $88.5 million, and sales and marketing expenses saw a significant 30% jump to $104.3 million, reflecting investments in commercial expansion and product launches. General and administrative expenses also increased by 21% to $47.0 million. These higher expenses contributed to a net loss of $95.2 million for the quarter, although this is an improvement from the $115.0 million net loss in the prior year period.
What is the company's current financial liquidity position?
Guardant Health maintains a strong liquidity position, with cash, cash equivalents, and restricted cash totaling $803.9 million as of March 31, 2025. The company believes this is sufficient to meet its operating requirements for more than the next 12 months.
Are there any significant debt management activities or legal developments to note?
In February 2025, the company completed a note exchange, retiring $659.3 million of its 2027 Convertible Senior Notes in exchange for $600.0 million of new 1.25% Convertible Senior Notes due 2031. This transaction resulted in a $13.7 million gain on extinguishment. Regarding legal matters, a jury verdict in November 2023 favored TwinStrand Biosciences, resulting in an $83.4 million damages award against Guardant Health, which the company is contesting. Separately, Guardant Health won a $292.5 million jury award against Natera in May 2024 for false advertising, though post-trial briefings are ongoing.
06—Continue